Answers are grounded in this paper and cite their sources.
Tenofovir/lamivudine/dolutegravir (TLD) is the preferred first-line antiretroviral therapy (ART) regimen for people with HIV (PWH), including those who were previously virologically suppressed on nonnucleoside reverse transcriptase inhibitors (NNRTIs). We sought to estimate the real-world effectiveness of the TLD transition in Ugandan public-sector clinics.
No takes yet. Share an insight, caveat, or question.
McCluskey et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: